<DOC>
	<DOCNO>NCT02455089</DOCNO>
	<brief_summary>Given GADD34 describe potential key regulator pro-inflammatory cytokine production human elevate blood marker SLE patient , study aim prove GADD34 RNA level mononuclear blood cell use prognostic marker ass risk SLE flare .</brief_summary>
	<brief_title>Prognosis Assessment Increase GADD34 Gene Expression Patient Suffering From Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Systemic lupus erythematosus ( SLE ) prevalence estimate 1 6 per 10000 individual concern 30 000 patient France example . As today , n't reliable specific blood analysis use assess prognosis SLE , mean predict SLE flare . The discovery blood test could allow good patient ' monitoring order help doctor well adapt treatment ( lower background treatment need increase ahead potential flare risk assessment raise ) . In SLE patient , recent study show elevate level GADD34 RNA mononuclear blood cell : high twice control level 36 60 SLE patient ten time higher control level 13 60 SLE patient . Given GADD34 describe potential key regulator pro-inflammatory cytokine production human elevate blood marker SLE patient , study aim prove GADD34 RNA level mononuclear blood cell use prognostic marker ass risk SLE flare .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>man woman 18 Years old . suffer SLE ( American College Rheumatology criterion ) . without SLE flare 3 month . sign consent social security affiliation ( require France ) . Viral infection within 15 day . Other chronic inflammatory disease . People special protection ( defined article : L1121 ยง58 et article L3212ยง13 French health care law ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Flare</keyword>
	<keyword>Therapeutic adjustment</keyword>
	<keyword>Biological Marker</keyword>
	<keyword>Immunologic Marker</keyword>
	<keyword>Prognosis</keyword>
</DOC>